Send us Fan Mail GLP-1 drugs have transformed the conversation around weight loss, but could they also play a role in managing inflammatory bowel disease (IBD)? In this episode of Wrestling the Octopus IBD, we are joined by a world leader in gastroenterology, Dr David Rubin, professor of gastroenterology, hepatology and nutrition at the University of Chicago. He educates our listeners on what these medications could mean for people living with Crohn's disease and ulcerative colitis. Dr Rubin explains how GLP-1 drugs work beyond appetite suppression, including their effects on gut motility, metabolism, inflammation and overall gut health. The discussion looks at why obesity and excess body fat have become increasingly common in people with IBD, and how reducing inflammation associated with fat tissue may potentially benefit long-term health. The conversation explores emerging research into GLP-1 drugs such as semaglutide and tirzepatide, including studies investigating whether they may help reduce intestinal inflammation alongside traditional IBD treatments. Dr Rubin shares insights from his own clinical practice, where these medications are already being used in selected patients with Crohn's disease and ulcerative colitis. One of the most fascinating themes in this episode is the emerging field of immunometabolic health. Dr Rubin explains how metabolism, body fat and the immune system are closely connected, and why improving metabolic health may help reduce inflammation in people with Crohn's disease and ulcerative colitis. The discussion explores whether GLP-1 drugs could offer benefits beyond weight loss, potentially becoming part of a broader approach to inflammatory bowel disease care. Dr Rubin also discusses important practical considerations, including side effects, nutritional monitoring, exercise, muscle loss and the need for careful medical supervision. The episode addresses who may benefit from GLP-1 treatment, who may need additional caution and why symptom improvement does not necessarily mean underlying inflammatory bowel disease is under control. Along the way, the discussion covers rapid gut transit in people with ileostomies and J-pouches, mesenteric fat, intestinal ultrasound, immunometabolic health and why comprehensive care should focus on the whole person, not just the bowel. There is even time for a lively diversion into bile acid malabsorption, one of Nigel's favourite topics. Whether you are considering GLP-1 drugs for weight loss, curious about the latest Crohn's disease and ulcerative colitis research or interested in the future of gut health and IBD care, this episode offers a balanced and evidence-based look at one of the most talked-about developments in gastroenterology. In this episode: Why GLP-1 drugs are generating so much interest in IBDHow GLP-1 medications affect appetite, digestion and gut motilityThe links between obesity, inflammation and inflammatory bowel diseaseWhether GLP-1 drugs may help people with Crohn's disease and ulcerative colitisCurrent research into semaglutide, tirzepatide and IBDPotential benefits for people with ileostomies and J-pouchesSide effects, safety considerations and monitoringThe importance of nutrition, exercise and preserving muscle massNew developments in intestinal ultrasound and personalised IBD careWhat the next five years of GLP-1 and gut health research might look likeFollow Rachel at @bottomlineibd Follow Nigel at @crohnoid